Suppr超能文献

[2008年至2013年河南省艾滋病患者启动抗逆转录病毒治疗后的HIV抑制效果及相关因素分析]

[Analysis on HIV suppression effect after initiating antiretroviral treatment and related factors among AIDS patients in Henan province during 2008 and 2013].

作者信息

Yang Wenjie, Fan Panying, Liang Yan, Li Jie, Ma Yanmin, Li Ning, Sun Dingyong, Zhu Qian, Wang Zhe

机构信息

Institute for AIDS/STD Prevention and Cure, Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450016, China.

Institute for AIDS/STD Prevention and Cure, Henan Provincial Center for Disease Control and Prevention, Zhengzhou 450016, China. Email:

出版信息

Zhonghua Yu Fang Yi Xue Za Zhi. 2015 Jan;49(1):13-20.

Abstract

OBJECTIVE

To compare the HIV suppression rate after initiating antiretroviral treatment(ART) among AIDS patients at different immunological levels and to analyze the related factors.

METHODS

Data on AIDS patients initially starting antiretroviral therapy during 2008 and 2013 were collected from Chinese HIV/AIDS integrated control system. All the participants were divided into early treatment group(baseline CD4(+)T cell counts between 351/µl and 500/µl) and conventional treatment group(baseline CD4(+)T cell counts ≤ 350/µl). The rates of comprehensive virologic suppression at different time nodes after the initiation of ART were analyzed accordingly. Unconditional logistic regression model was adopted to examine the factors associated with the failure of viral suppression after 6 months after initiation of ART.

RESULTS

A total of 16 103 cases were selected, among which, 1 581 cases were early treatment group, and 14 522 cases were conventional treatment group. A total of 9 428 cases were males, 6 675 cases were females, and the sex ratio was 1.41: 1. The age was 47.2 ± 11.7, and 71.55% (11 522/16 103) of cases were married or cohabiting, 57.22% (9 214/16 103) were transmitted by blood. 81.26% (13 086/16 103) were cures in the township or village treatment institution, and 77.17% (12 426/16 103) received the ART regimen as Stavudine(D4T) or Zidovudine(AZT)+Lamivudine(3TC)+Nevirapine(NVP) or Efevirenz(EFV). After 0.5, 1, 2, 3, 4, 5 and 6 years after the initiation of ART, the rates of virologic suppression in the conventional treatment cohort were 72.6% (3 008/4 144), 73.9% (4 758/6 443), 74.1% (3 641/4 915), 74.9% (2 819/3 766), 76.1% (1 729/2 272) and 78.2% (492/629), respectively. While the rates of viral suppression in the early treatment cohort at the same time nodes were 65.5% (315/481), 65.4% (448/685), 68.8% (223/324), 66.0% (155/235), 71.4% (110/154) and 61% (30/49), respectively, and the differences between the two groups were significant (P < 0.05) except at the fourth year. Non-conditional logistic regression analysis showed that in the conventional treatment group, factors associated with low HIV suppression rate were male (OR = 1.23, 95%CI:1.07-1.42) , longer time interval from confirmed HIV infection to received ART (OR = 1.26, 95%CI:1.16-1.36) , using D4T/AZT+ DDI +NVP/EFV as initial treatment regimen (OR = 3.00, 95%CI:2.26-3.98) and nearly missing doses for 7 days at treatment of six months (OR = 1.97, 95%CI:1.22-3.18) and factors associated with high HIV suppression rate were infected through homosexual transmission route (OR = 0.57, 95%CI:0.35-0.90) and treated in the county level medical institution or above (OR = 0.61, 95%CI:0.50-0.75) . Among early treatment group, cases who received treatment at county level medical institution or above had high HIV suppression rate (OR = 0.43, 95%CI:0.23-0.80) and objects with longer time interval from confirmed HIV infection to receive ART had low HIV suppression rate (OR = 1.43, 95%CI:1.09-1.88).

CONCLUSION

The viral suppression efficacy among AIDS patients with different baseline immunologic levels after treatment was similarly satisfactory. AIDS cases who received ART at county level medical institution or above had better viral suppression effect and patients with longer time interval from confirmation to treatment had poor HIV suppression effect.

摘要

目的

比较不同免疫水平的艾滋病患者启动抗逆转录病毒治疗(ART)后的HIV抑制率,并分析相关因素。

方法

从中国HIV/AIDS综合防治系统收集2008年至2013年开始接受抗逆转录病毒治疗的艾滋病患者数据。所有参与者分为早期治疗组(基线CD4(+)T细胞计数在351/µl至500/µl之间)和常规治疗组(基线CD4(+)T细胞计数≤350/µl)。相应分析ART启动后不同时间节点的综合病毒学抑制率。采用无条件逻辑回归模型检验ART启动后6个月病毒抑制失败的相关因素。

结果

共入选16103例,其中早期治疗组1581例,常规治疗组14522例。男性9428例,女性6675例,性别比为1.41:1。年龄为47.2±11.7岁,71.55%(11522/16103)的病例已婚或同居,57.22%(9214/16103)通过血液传播。81.26%(1308/16103)在乡镇或村级治疗机构治愈,77.17%(12426/16103)接受司他夫定(D4T)或齐多夫定(AZT)+拉米夫定(3TC)+奈韦拉平(NVP)或依非韦伦(EFV)的ART方案。ART启动后0.5、1、2、3、4、5和6年,常规治疗队列的病毒学抑制率分别为72.6%(3008/4144)、73.9%(4758/6443)、74.1%(3641/4915)、74.9%(2819/3766)、76.1%(1729/2272)和78.2%(492/从629)。而早期治疗队列在相同时间节点的病毒抑制率分别为65.5%(315/481)、65.4%(448/685)、68.8%(223/324)、66.0%(155/235)、71.4%(110/154)和61%(30/49),除第四年外两组差异有统计学意义(P<0.05)。非条件逻辑回归分析显示,在常规治疗组中,与HIV抑制率低相关的因素为男性(OR = 1.23,95%CI:1.07 - 1.42)、从确诊HIV感染到接受ART的时间间隔较长(OR = 1.26,95%CI:1.16 - 1.36)、使用D4T/AZT + DDI + NVP/EFV作为初始治疗方案(OR = 3.00,95%CI:2.26 - 3.98)以及治疗6个月时近7天漏服药物(OR = 1.97,95%CI:1.22 - 3.18),与HIV抑制率高相关的因素为通过同性传播途径感染(OR = 0.57,95%CI:0.35 - 0.90)以及在县级及以上医疗机构治疗(OR = 0.61,95%CI:0.50 - 0.75)。在早期治疗组中,在县级及以上医疗机构接受治疗的病例HIV抑制率高(OR = 0.43,95%CI:0.23 - 0.80),从确诊HIV感染到接受ART时间间隔较长的对象HIV抑制率低(OR = 1.43,95%CI:1.09 - 1.88)。

结论

不同基线免疫水平的艾滋病患者治疗后的病毒抑制效果同样令人满意。在县级及以上医疗机构接受ART的艾滋病病例病毒抑制效果较好,确诊到治疗时间间隔较长的患者HIV抑制效果较差。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验